CU6 - Media and Industry News, page-521

It really is going to depend on dose. If an Ac225bisPSMA construct can get more of the Ac225 to the tumour then you can reduce the dose and avoid causing the kidney damage that comes with renal excretion.

I don’t think CU6 is running a Ac225 program because they really believe it is needed, but it is a program designed to appeal a big player that does believe in Ac225. What I want to hear more about is the click chemistry technology they bought a little while back. That has the potential to really revolutionise radiotheranostics and we have heard nothing much about it since the purchase,